Fennec Pharmaceuticals Inc (NASDAQ:FENC) COO Adrian Haigh Sells 22,222 Shares

Fennec Pharmaceuticals Inc (NASDAQ:FENC) COO Adrian Haigh sold 22,222 shares of Fennec Pharmaceuticals stock in a transaction on Wednesday, April 17th. The stock was sold at an average price of $9.91, for a total value of $220,220.02. Following the transaction, the chief operating officer now directly owns 22,222 shares of the company’s stock, valued at approximately $220,220.02. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Adrian Haigh also recently made the following trade(s):

• On Monday, April 15th, Adrian Haigh sold 22,222 shares of Fennec Pharmaceuticals stock. The stock was sold at an average price of $10.30, for a total value of $228,886.60.

Fennec Pharmaceuticals Trading Down 1.3 %

Shares of FENC stock opened at $9.57 on Friday. The firm has a 50-day moving average price of $10.10 and a 200 day moving average price of $9.33. Fennec Pharmaceuticals Inc has a twelve month low of $6.30 and a twelve month high of $11.92. The company has a market capitalization of $259.35 million, a price-to-earnings ratio of -15.69 and a beta of 0.38.

Fennec Pharmaceuticals (NASDAQ:FENC) last posted its quarterly earnings data on Thursday, March 21st. The company reported ($0.10) EPS for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.12). The firm had revenue of $9.74 million for the quarter, compared to the consensus estimate of $9.47 million. As a group, research analysts predict that Fennec Pharmaceuticals Inc will post 0.11 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of FENC. Sonic GP LLC purchased a new stake in shares of Fennec Pharmaceuticals during the 4th quarter worth about $23,111,000. Vanguard Group Inc. grew its holdings in shares of Fennec Pharmaceuticals by 1,294.3% during the 4th quarter. Vanguard Group Inc. now owns 1,140,063 shares of the company’s stock worth $12,792,000 after purchasing an additional 1,058,295 shares during the period. BlackRock Inc. grew its holdings in shares of Fennec Pharmaceuticals by 1,507.6% during the 2nd quarter. BlackRock Inc. now owns 830,119 shares of the company’s stock worth $7,330,000 after purchasing an additional 778,481 shares during the period. AIGH Capital Management LLC grew its holdings in shares of Fennec Pharmaceuticals by 6.9% during the 3rd quarter. AIGH Capital Management LLC now owns 373,526 shares of the company’s stock worth $2,805,000 after purchasing an additional 24,069 shares during the period. Finally, Gendell Jeffrey L grew its holdings in shares of Fennec Pharmaceuticals by 0.9% during the 3rd quarter. Gendell Jeffrey L now owns 285,992 shares of the company’s stock worth $2,148,000 after purchasing an additional 2,579 shares during the period. Institutional investors and hedge funds own 55.51% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently weighed in on the stock. Wedbush reissued an “outperform” rating and issued a $16.00 target price on shares of Fennec Pharmaceuticals in a research note on Monday, March 18th. Craig Hallum boosted their target price on shares of Fennec Pharmaceuticals from $17.00 to $18.00 and gave the company a “buy” rating in a research note on Monday, March 18th. Finally, HC Wainwright boosted their target price on shares of Fennec Pharmaceuticals from $17.00 to $18.00 and gave the company a “buy” rating in a research note on Thursday, April 4th.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.